[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564927":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":25,"studyPopulation":25,"armGroups":47,"interventions":55,"overallOfficials":69,"centralContacts":74,"locations":83,"responsibleParty":132,"collaborators":25,"id":134,"slug":25,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":135,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":25,"studyType":147,"phases":148,"briefSummary":149,"conditions":150,"keywords":25,"overallStatus":86,"whyStopped":25,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},{"fullName":5,"class":6},"Fundacion Dexeus","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":25},[9,13,16,19],{"measure":10,"description":11,"timeFrame":12},"Estradiol","Estradiol levels","days 1, 6, 8, 10,the day of ovulation triggering, the day of ovulation triggering day+1 and 7 days after oocyte retrieval",{"measure":14,"description":15,"timeFrame":12},"Progesterone","Progesterone levels",{"measure":17,"description":18,"timeFrame":12},"Follicle stimulating hormone (FSH)","FSH levels",{"measure":20,"description":21,"timeFrame":12},"Luteinizing hormone (LH)","LH levels",[23,27,29,31,34,36,38],{"measure":24,"description":25,"timeFrame":26},"Days of stimulation",null,"7 -20 days from initiation of ovarian stimulation",{"measure":28,"description":25,"timeFrame":26},"Number of oocytes retrieved (COCs)",{"measure":30,"description":25,"timeFrame":26},"Number of MII oocytes",{"measure":32,"description":33,"timeFrame":26},"Follicular Output Rate (FORT)","expressed as the ratio between the total number of oocytes retrieved at oocyte pick-up and the number of antral follicles available at the start of stimulation",{"measure":35,"description":33,"timeFrame":26},"Follicle-to-oocyte index (FOI)",{"measure":37,"description":25,"timeFrame":26},"Cancellation rate",{"measure":39,"description":25,"timeFrame":40},"Ovarian hyperstimulation syndrome (OHSS) rate","Until 15 days after punction",{"allocation":42,"interventionModel":43,"interventionModelDescription":25,"primaryPurpose":44,"observationalModel":25,"timePerspective":25,"maskingInfo":45},"NA","SINGLE_GROUP","TREATMENT",{"masking":46,"maskingDescription":25,"whoMasked":25},"NONE",[48],{"label":49,"type":50,"description":25,"interventionNames":51},"Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg\u002Fday from D1","EXPERIMENTAL",[52,53,54],"Drug: Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg\u002Fday from D1","Drug: Clomiphene Citrate (CC) 100 mg\u002Fday from D1","Diagnostic Test: Monitoring cycle",[56,60,64],{"type":57,"name":49,"description":58,"armGroupLabels":59,"otherNames":25},"DRUG","On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.",[49],{"type":57,"name":61,"description":62,"armGroupLabels":63,"otherNames":25},"Clomiphene Citrate (CC) 100 mg\u002Fday from D1","On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100\u002Fday continuing up to and including the day of ovulation triggering",[49],{"type":65,"name":66,"description":67,"armGroupLabels":68,"otherNames":25},"DIAGNOSTIC_TEST","Monitoring cycle","Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.",[49],[70],{"name":71,"affiliation":72,"role":73},"Nikolaos P Polyzos, MD, PhD","Dexeus Fertility","PRINCIPAL_INVESTIGATOR",[75,79],{"name":71,"role":76,"phone":77,"phoneExt":25,"email":78},"CONTACT","0034932274700","nikpol@dexeus.com",{"name":80,"role":76,"phone":77,"phoneExt":81,"email":82},"Ignacio Rodríguez, MSc","22029","nacrod@dexeus.com",[84,103,115],{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":98},"Dexeus Mujer Sabadell","RECRUITING","Sabadell","Barcelona","08203","Spain","ES",{"type":93,"coordinates":94},"Point",[95,96],2.10942,41.54329,{"lat":96,"lon":95},[99,101],{"name":100,"role":76,"phone":25,"phoneExt":25,"email":25},"Silvia Grau, MD",{"name":102,"role":73,"phone":25,"phoneExt":25,"email":25},"Silvia Grau",{"facility":104,"status":86,"city":105,"state":88,"zip":106,"country":90,"countryCode":91,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Dexeus Mujer Sant Cugat","Sant Cugat del Vallès","08195",{"type":93,"coordinates":108},[109,110],2.08611,41.47063,{"lat":110,"lon":109},[113,114],{"name":100,"role":76,"phone":25,"phoneExt":25,"email":25},{"name":100,"role":73,"phone":25,"phoneExt":25,"email":25},{"facility":116,"status":117,"city":88,"state":25,"zip":118,"country":90,"countryCode":91,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus","NOT_YET_RECRUITING","08037",{"type":93,"coordinates":120},[121,122],2.15899,41.38879,{"lat":122,"lon":121},[125,127,129],{"name":126,"role":76,"phone":77,"phoneExt":81,"email":82},"Ignacio Rodríguez, BsC",{"name":128,"role":73,"phone":25,"phoneExt":25,"email":25},"Nikolaos P Polyzos, MD PhD",{"name":130,"role":131,"phone":25,"phoneExt":25,"email":25},"Valeria Donno, MD","SUB_INVESTIGATOR",{"type":133,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100564927",false,"NCT06635538","One-shot Ovarian Stimulation Protocol (One-shot)","One-Shot Ovarian Stimulation Protocol: A Pilot Study Investigating the Endocrine Profile","One-shot","Inclusion Criteria:\n\nAge \\\u003C= 40\n\nAMH (Anti-Mullerian Hormone) 1.2-3.5 ng\u002Fml or AFC 7-20\n\nNo family history of hereditary or chromosomal diseases\n\nBody mass index (BMI) 18 to 30 kg\u002Fm2","FEMALE","18 Years","40 Years",{"count":145,"type":146},20,"ESTIMATED","INTERVENTIONAL",[42],"The current prospective observational pilot study aims to evaluate the endocrine profile of a single-injection protocol (single CFA + daily oral administration of CC).",[151],"Infertility, Female","2025-02-25",{"date":154,"type":155},"2025-02-26","ACTUAL",{"date":157,"type":155},"2024-10-31",{"date":159,"type":146},"2025-04",{"name":161,"class":6},"Fundación Santiago Dexeus Font",3]